-
Clinical trials of pharmacotherapy to prevent progression of cognitive decline in those with mild cognitive impairment (MCI) have been disappointing; neither cholinesterase inhibitors (donepezil, rivastigmine, galantamine), vitamin E, nor COX-2 inhibitors has demonstrated any clinically meaningful benefit in placebo-controlled MCI trials.
-
Estrogen treatment (but not estrogen given along with progestin) seems associated with gastro-esophageal reflux (GER) in postmenopausal women. Weight gain increases risk.
-
-
Regardless of where we practice, increasingly we are confronted with patients who have been exposed to unusual diseases through travel. In a previous series of articles, we reviewed the diseases associated with travel, largely based on the geography. This article reviews infectious disease associated with travel by symptoms.
-
Some women with DVT may stop warfarin after six months; Vytorin and cancer; preventing recurrent stroke; and FDA news.
-
The anti-angiogenic monoclonal antibody, bevacizumab, shows great promise in the treatment of malignant gliomas.
-
The Babinski sign continues to be a valid bed-side test for pyramidal tract lesions.
-
Platelet function testing identifies patients who do not respond to antiplatelet therapy and are at increased risk for acute stent thrombosis after neurointerventional procedures.
-
-